BeiGene CEO John Oyler at BIIS18 (Endpoints News, PharmCube)
September 19, 2023 06:47 AM EDT
Deals
R&D
FDA+

No­var­tis hands back PD-1 in­hibitor to BeiGene af­ter reg­u­la­to­ry hur­dles

Kyle LaHucik

Senior Reporter

BeiGene will re­gain the full glob­al rights to its an­ti-PD-1 an­ti­body tislelizum­ab from No­var­tis af­ter the com­pa­nies ran in­to reg­u­la­to­ry hur­dles in the US …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times